What is the price-to-earnings ratio of ImmunoGen?
The price-earnings ratio of ImmunoGen is currently 72.79.
ImmunoGen P/S 2025
ImmunoGen P/S
72.79
Ticker
IMGN
ISIN
US45253H1014
WKN
878613
As of Oct 7, 2025, ImmunoGen's P/S ratio stood at 72.79, a 415.51% change from the 14.12 P/S ratio recorded in the previous year.
The ImmunoGen P/S history
ImmunoGen Aktienanalyse
What does ImmunoGen do?
ImmunoGen Inc is a leading company in the biotechnology industry. The company was founded in 1981 as a research facility. In recent decades, ImmunoGen Inc has specialized in the development of antibody-drug conjugates (ADCs). ADCs are drugs that consist of an antibody and a cytotoxin that specifically targets tumor cells. In this way, cancer cells can be selectively destroyed without damaging surrounding tissue. ImmunoGen Inc has achieved success in recent years, particularly in the development of ADCs against serious cancers such as lung cancer or breast cancer, and it also collaborates with major pharmaceutical companies such as Roche or Bayer. The business model of ImmunoGen Inc, therefore, consists of developing innovative cancer drugs and successfully bringing them to market. Another branch of the company is the development of therapeutics for other diseases such as rheumatoid arthritis or multiple sclerosis. ImmunoGen Inc also utilizes ADCs to selectively destroy disease-specific cells in these cases. In the past, ImmunoGen Inc has successfully launched several products on the market. For example, in 2019, the cancer drug Kadcyla, manufactured by Roche and based on ImmunoGen's ADC technology, was approved by the US Food and Drug Administration (FDA) for the treatment of certain types of breast cancer. The ADC development candidate IMGN632 also shows promising results in the treatment of acute myeloid leukemia and other cancer diseases. The history of ImmunoGen Inc has also been marked by some challenges. In the early years of the company, it faced financial difficulties and sold a large number of shares to an investor in 1999. However, the company remained diligent in research and development and eventually became one of the leading biotech companies in the field of cancer research with the development of ADCs. Nevertheless, the company has also experienced setbacks in the development of products and has had to discontinue several development programs. Despite everything, ImmunoGen Inc is considered a successful company in the biotechnology industry, effectively marketing its innovative solutions in the oncology market. It is also being closely watched to see whether future ADCs will not have to undergo as long development cycles as their predecessors, which can guarantee long-term success for the company. ImmunoGen ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding ImmunoGen's P/S Ratio
ImmunoGen's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing ImmunoGen's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating ImmunoGen's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in ImmunoGen’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about ImmunoGen stock
How has the price-earnings ratio of ImmunoGen changed compared to last year?
The price-to-earnings ratio of ImmunoGen has increased by 415.51% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of ImmunoGen high compared to other companies?
Yes, the price-to-earnings ratio of ImmunoGen is high compared to other companies.
How does an increase in the price-earnings ratio of ImmunoGen affect the company?
An increase in the price-earnings ratio of ImmunoGen would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of ImmunoGen affect the company?
A decrease in the price-earnings ratio of ImmunoGen would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of ImmunoGen?
Some factors that influence the price-earnings ratio of ImmunoGen are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does ImmunoGen pay?
Over the past 12 months, ImmunoGen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImmunoGen is expected to pay a dividend of 0 USD.
What is the dividend yield of ImmunoGen?
The current dividend yield of ImmunoGen is .
When does ImmunoGen pay dividends?
ImmunoGen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImmunoGen?
ImmunoGen paid dividends every year for the past 0 years.
What is the dividend of ImmunoGen?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImmunoGen located?
ImmunoGen is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImmunoGen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImmunoGen from 10/7/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/7/2025.
When did ImmunoGen pay the last dividend?
The last dividend was paid out on 10/7/2025.
What was the dividend of ImmunoGen in the year 2024?
In the year 2024, ImmunoGen distributed 0 USD as dividends.
In which currency does ImmunoGen pay out the dividend?
The dividends of ImmunoGen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ImmunoGen
Our stock analysis for ImmunoGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmunoGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
